Circulating MIC-1/GDF15 is a complementary screening biomarker with CEA and correlates with liver metastasis and poor survival in colorectal cancer.
Circulating MIC-1/GDF15 is a complementary screening biomarker with CEA and correlates with liver metastasis and poor survival in colorectal cancer.
复制标题
循环 MIC-1/GDF15 是与 CEA 互补的筛查生物标志物，与结直肠癌的肝转移和不良生存相关
DOI：
10.18632/oncotarget.15279
复制
发表时间：
2017-04-11
期刊：
影响因子：
--
通讯作者：
Zhang W
中科院分区：
文献类型：
--
作者：
Wang X;Yang Z;Tian H;Li Y;Li M;Zhao W;Zhang C;Wang T;Liu J;Zhang A;Shen D;Zheng C;Qi J;Zhao D;Shi J;Jin L;Rao J;Zhang W
巨噬细胞抑制性细胞因子 1 (MIC-1/GDF15) 最近被定性为结直肠癌 (CRC) 的候选生物标志物。然而，血清MIC-1在筛查早期CRC患者和监测治疗反应中的作用尚未明确，特别是与CEA联合用于筛查和预判肝转移的发生。在这项研究中，我们使用 ELISA 或免疫测定法对来自 473 名 CRC 患者、25 名腺瘤性息肉患者和 489 名健康个体的 987 份血清样本进行了回顾性盲法评估。血清MIC-1对CRC诊断和早期诊断的敏感性分别为43.8%和38.5%，独立于CEA（36.6%和27.3%），且特异性较高。术后血清MIC-1在肿瘤复发时显着升高，100%肝转移患者观察到显着升高。除了 TNM 分类和分化分级外，MIC-1 是影响总生存率的独立预后因素。我们的结论是，MIC-1 可以作为联合 CEA 筛查早期 CRC 的候选补充生物标志物，此外，首次确定了一个有希望的预后指标，用于监测肝转移复发，以支持个性化治疗策略。
Macrophage inhibitory cytokine 1 (MIC-1/GDF15) has been characterized as a candidate biomarker for colorectal cancer (CRC) recently. However, the role of serum MIC-1 in screening patients with early stage CRC and monitoring therapeutic response have not been well-established, particularly in the combination with CEA for the screening and the prejudgment of occurrence with liver metastasis. In this study, we performed a retrospective blinded evaluation of 987 serum samples from 473 individuals with CRC, 25 with adenomatous polyps, and 489 healthy individuals using ELISA or immunoassay. The sensitivity of serum MIC-1 was 43.8% and 38.5% for CRC diagnosis and early diagnosis, respectively, which were independent of and comparatively higher than for CEA (36.6% and 27.3%) at comparable specificity. Serum MIC-1 after surgery were significantly elevated at the time of tumor recurrence, and notable increase were observed in 100% patients with liver metastasis. Besides the TNM classification and differentiation grade, MIC-1 was an independent prognostic factor contributing to overall survival. We conclude that MIC-1 can act as a candidate complementary biomarker for screening early-stage CRC by combination with CEA, and furthermore, for the first time, identify a promising prognostic indicator for monitoring recurrence with liver metastasis, to support strategies towards personalized therapy.